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http://dxObjectives:Major trauma is a leading cause of death, particularly among young patients. New strategies in man-
agement are needed to improve poor outcomes in cases of severe trauma. Extracorporeal life support (ECLS) has
proven to be effective in acute cardiopulmonary failure of different causes, even when conventional therapies
fail. We report our initial experience with ECLS as a rescue therapy in severely polytraumatized patients in a re-
fractory clinical setting. This study identifies the pre-ECLS characteristics of patients to predict the appropriate-
ness of ECLS treatment.
Methods: FromDecember 2008 to May 2012, 375 patients with polytrauma were treated in the Careggi Teach-
ing Hospital, a tertiary-level referral trauma center. Our ECLS team was alerted on 30 patients and applied
ECLS in 18 adult patients with trauma. We adopted venoarterial ECLS in 14 patients with cardiopulmonary
failure with refractory shock and venovenous ECLS in 4 patients with isolated refractory acute respiratory
failure.
Results: ECLS was initiated at a mean of 359.176 216.606 (145-950) minutes from trauma. In 4 patients, the
ECLS treatment failed because of an incapability to maintain adequate ECLS flow and perfusion. In 14 patients,
efficiently supported by ECLS, the cardiac index, mean arterial pressure, blood lactate concentration, arterial
oxygen tension, arterial carbon dioxide tension, and pH showed significant improvement, with normal values
reached at 3.5  1.5 hours.
Conclusions: From our data, ECLS seems to be a valuable option to resuscitate patients with severe trauma
when conventional therapies are insufficient. ECLS is safe, feasible, and effective in providing hemodynamic
support and blood gas exchange. (J Thorac Cardiovasc Surg 2013;145:1617-26)/B
SMajor trauma is a leading cause of death, particularly
among young patients, occurring in more than 5 million
persons worldwide each year.1 Death by trauma can oc-
cur in 3 ways. Immediate death (on stage) is caused by
untreatable injuries, such as aortic rupture or cervical spi-
nal lesions. Early causes of death (hours to a few days)
are severe and usually related to severe hemorrhage, pul-
monary failure, cardiovascular shock, or extensive brain
injury. Late deaths (days to weeks) are usually due to
secondary infections or multiple organ failure. Early
causes of death are the most important in determining
the poor outcome of severe trauma; a dramatic decline
in survival has been noted in the first 10 days of hospital
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TConventional therapies for post-traumatic cardiovascu-
lar shock and acute pulmonary failure may be insufficient
and even dangerous. Massive blood transfusions, even if
effective in restoring blood volume, may have a disastrous
effect on blood coagulation, acid-base balance, and lung
(transfusion-related acute lung injury) and organ perfu-
sion.3-5 Aggressive mechanical ventilation strategies in
case of refractory pulmonary failure can worsen lung
function by inducing ventilator-induced lung injury.6-8
High doses of vasoconstrictor/inotropic drugs may have
a disastrous effect on the heart and microcirculation,
inducing severe heart dysfunction, myocardial stunning,
and worsening organ perfusion.1,4,5,9,10 All of these
physiopathologic effects due to conventional treatment
may create an unavoidable and potentially lethal vicious
circle.
New approaches in trauma care and advanced treatments
are needed to modify the actual therapeutic strategy and
treatment protocols. Extracorporeal life support (ECLS)
has proven to be effective in shock status and pulmonary
failure, even when standard therapies have failed.9-11
ECLS can provide full hemodynamic support (in
venoarterial [VA] configuration) in cases of refractory
shock unresponsive to conventional treatment, allowing
time for diagnosis and heart recovery. Moreover, even indiovascular Surgery c Volume 145, Number 6 1617
Abbreviations and Acronyms
BL ¼ blood lactate
CA ¼ cardiac arrest
CI ¼ confidence interval
ECLS ¼ extracorporeal life support
IS ¼ inotropic score
ISS ¼ injury severity score
OR ¼ odds ratio
PaO2 ¼ arterial oxygen tension
ROC ¼ receiver operating characteristic
VA ¼ venoarterial
VV ¼ venovenous
Evolving Technology/Basic Science Bonacchi et al
E
T
/B
Scases of refractory pulmonary failure, complete gas
exchange is ensured by ECLS (in venovenous [VV]
configuration), improving blood oxygenation and carbon
dioxide removal, allowing time for lung recovery, and
reducing mechanical ventilation invasiveness.
Nevertheless, the need for anticoagulation to prevent
clot formation in the circuit has not allowed the widespread
use of ECLS in patients with polytrauma until recently,
mostly because of multiple injuries and increased risk of
bleeding. Since the first use of ECLS in a patient with
trauma, performed by Donald Hill in 1972,12 many
changes and improvements in devices and materials bio-
compatibility have made the deployment of ECLS safer
and easier even in complex and polytraumatized pa-
tients.9-11,13 Heparin-coated circuits decrease blood coagu-
lation activation and allow starting heparin-free ECLS,
delaying heparin administration for just 48/72 hours.5,13
Percutaneous cannulation and double-lumen catheters
(for VV-ECLS) enable less-invasive and faster procedures
that are suitable for emergency situations. Oxygenators and
centrifugal pumps have become more compatible with
blood, reducing hemolysis and platelet consumption, and
the need for blood component transfusions. In adjunct,
as suggest by Larsson and colleagues,13 there is a possible
favorable role for VA-ECLS in controlling venous hemor-
rhage by reducing central venous pressure with active
drainage from this area.
We report our initial experience in initiating ECLS as
a rescue therapy in patients with severe trauma in a severe
clinical setting (cardiogenic shock, cardiac arrest [CA], or
pulmonary failure) who have been shown to be refractory
to conventional treatments. The rationale for using ECLS
in patients with trauma is to treat refractory pulmonary
and cardiopulmonary failure, provide adequate systemic
perfusion, avoid consequent multiple organ failure, and per-
mit organ recovery.5,14,15 Furthermore, we have identified
several polytraumatized patient characteristics as
predictors of the appropriateness of ECLS treatment. In
addition, ECLS in select polytraumatized patients may be1618 The Journal of Thoracic and Cardiovascular Surused to support vital functions, allowing time for adequate
brain assessment.16,17MATERIALS AND METHODS
An ECLS program has been used since 2006 in the Careggi Teaching
Hospital (Florence, Italy) with collaboration between the emergency de-
partment and the heart and vessel department. Our ECLS team, composed
of a cardiac surgeon, an anesthesiologist, a cardiologist, and a perfusionist,
provides 24-hour coverage for emergencies with a fully deployed reaction
time of 20 minutes. The team ensures both indoor and out-of-center ECLS
deployment, with a dedicated and fully equipped ambulance.18 Generally
speaking, because of the invasiveness and high hemorrhagic risk, ECLS
is started when the team is convinced that standard therapies have been ex-
hausted and no improvement is anticipated, but the patient’s injuries are
considered to be potentially reversible with adequate life support.
From December 2008 to May 2012, 375 polytraumatized patients were
treated in our hospital, and our ECLS team was alerted for 30 (8%) of
these. In 12 patients, ECLS was not started because of massive and intrac-
table bleeding (skeletal, retroperitoneal, aortic lesions, n ¼ 8), certain pro-
longed hypoxemia (n¼ 2), and advanced age (>75 years, n¼ 2). The other
18 adult patients with trauma (mean age, 46.3  17.6 years [range, 15-69
years]; mean injury severity score [ISS], 53  17 [range, 18-75]) under-
went ECLS for refractory cardiopulmonary failure. Data of polytrauma-
tized patients who received ECLS support were prospectively collected
in our database (Table 1). Depending on the patient’s clinical condition,
mainly worsening of cardiocirculatory and pulmonary function, we initi-
ated ECLS in the emergency department (n ¼ 6) or operating room
(n ¼ 2) during damage control surgery, or in the intensive care unit
(n ¼ 10) (Figure 1).
Initiating Extracorporeal Life Support
ECLS was initiated after a fast clinical and instrumental reevaluation
performed by ECLS team members, collegially with emergency depart-
ment staff. ECLS contraindications were judged as follows: advanced
age (>65/70 years), witnessed prolonged hypoxemia (eg, prolonged ineffi-
cacious resuscitation in trauma department), potentially fatal preexisting
disease, and incontrollable major bleeding (eg, aortic rupture). When pos-
sible (in 12 patients, 66.7% of total), we performed a total-body computed
tomography scan before deciding to perform ECLS. The idea behind this
was to identify complete injury patterns and eventually the presence of hid-
den absolute contraindications.
The indication for VA-ECLS (n ¼ 14 patients, 77.8%) was cardiopul-
monary failure with shock (n ¼ 3, 16.7%) or post-traumatic CA (n ¼ 11
patients, 61.1%) that was refractory to conventional resuscitative treat-
ment. VV-ECLS (n ¼ 4 patients, 22.2%) was indicated instead in patients
with post-traumatic respiratory insufficiency with severe hypoxemia
(arterial oxygen tension [PaO2]/inspired oxygen fraction ratio<100) or hy-
percapnic acidosis that was refractory to advanced mechanical ventilation
management (Table 1). In all cases, a percutaneous cannulation procedure
was carried out by using the Seldinger technique without any skin incision,
thus preventing future cannula site bleeding. Transthoracic/transesopha-
geal ultrasonography was performed to guide and evaluate the position
and definitive setting of the cannulas.
In VA-ECLS cases, we adopted the femoro-femoral configuration; to
prevent leg ischemia, a small shunt cannula (8F-10F) was inserted in the
femoral artery distal to the ECLS cannula. In VV-ECLS, we used 2 cannu-
las in a femoro-jugular setting (n ¼ 2) or a single bilumen cannula (and
only 1 jugular access, n¼ 2). In case of VV-ECLS in a femoro-jugular set-
ting, we used a previously reported original technique, the c-configuration,
to optimize extracorporeal blood oxygenation.19 In all cases, because of
actual or potential bleeding risk, we initially performed heparin-free
ECLS until bleeding stopped and normalization of patient coagulative
status was achieved (Table 2).gery c June 2013
TABLE 1. Patient characteristics and outcome
Patient
Age,
y Gender ECLS indication
ACLS before
ECLS (min) ISS
ECLS
type
ECLS success
or failure Type of trauma Outcome
1 65 M Pulmonary contusion/pulmonary
failure
0 41 VV Success Blunt (car accident) Survived
2 37 M Pulmonary contusion/pulmonary
failure
0 75 VV Success Blunt (motorcycle accident) Survived
3 54 M Pulmonary contusion/pulmonary
failure
0 54 VV Success Blunt (car accident) Deceased
4 55 F Pulmonary contusion/bleeding
shock/CA
100 66 VA Success Blunt (car–pedestrian accident) Organ donation
5 68 M Bleeding shock/CA 80 38 VA Success Blunt (car accident) Organ donation
6 15 M Bleeding shock/CA 100 75 VA Failure Blunt (motorcycle accident) Deceased
7 46 M Bleeding shock/CA 75 18 VA Success Blunt (accidental fall) Organ donation
8 60 F Bleeding shock/CA 80 66 VA Failure Blunt (car–pedestrian accident) Deceased
9 46 F Bleeding shock/CA 90 67 VA Failure Blunt (car accident) Deceased
10 30 M Bleeding shock/CA 60 41 VA Success Blunt (motorcycle accident) Survived
11 16 M Bleeding shock/CA 30 38 VA Success Blunt (motorcycle accident) Survived
12 67 F Pulmonary contusion/bleeding
shock/CA
30 54 VA Success Blunt (car–pedestrian accident) Organ donation
13 54 M Bleeding shock 0 66 VA Success Blunt (motorcycle accident) Deceased
14 40 M Pulmonary contusion/pulmonary
failure
0 18 VV Success Blunt (crash) Survived
15 19 F Pulmonary contusion/pulmonary
failure
0 66 VA Success Blunt (car accident) Organ donation
16 69 F Bleeding shock 0 64 VA Success Blunt (car–pedestrian accident) Organ donation
17 40 M Bleeding shock/CA 40 50 VA Success Blunt (car accident) Deceased
18 52 M Bleeding shock/CA 80 52 VA Failure Blunt (accidental fall) Deceased
ECLS, Extracorporeal life support; ACLS, advanced cardiac life support; ISS, injury severity score; CA, cardiac arrest; VV, venovenous; VA, venoarterial.
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SExtracorporeal Life Support Circuit
The circuit we used consisted of a Rotaflow Maquet Centrifugal Pump
(MAQUET GmbH & Co KG, Rastatt, Germany) and a hollow fiber poly-
methylpentene membrane oxygenator (Quadrox-DOxygenator, MAQUET
GmbH & Co KG); the system is entirely ‘‘tip-to-tip’’ heparin coated. The
circuit includes a special intake stopcock for large-volume administration,
particularly effective in polytraumatized patients who require high-speed
fluid resuscitation.
Since November 2010, we have improved our instrumentation with the
CardioHelp system (MAQUET GmbH& Co KG), which is smaller and re-
quires minimal priming volume.We have applied it in this clinical scenario
in 4 patients. Depending on the patient’s biometric data, we used a 21F or
23F arterial cannula and a 25F, 27F, or 29F venous cannula (PLS femoral
cannula, MAQUET GmbH & Co KG) for VA and VV (in a double-
cannulation setting) ECLS. For VV-ECLS with a single cannula, we used
a 29F or 31F Elite bilumen cannula (Avalon Laboratories, LLC, Rancho
Dominguez, Calif). A heat-exchanger device was integrated in the ECLS
circuit to control the patient’s temperature.
Extracorporeal Life Support Management and
Weaning
Blood flow provided by ECLS should be maintained in the range of
physiologic cardiac output, and gas supply to the oxygenator should be reg-
ulated to reach normal blood gas concentrations, adapting them to the
patient’s biometric data, to achieve normal perfusion indexes (eg, acidosis,
lactate blood concentration, and mixed venous oxygen saturation) and to
avoid the adverse effects of hyperoxygenation or hypocapnia.
In VA-ECLS, inotropic drug infusion was progressively decreased ac-
cording to the mean arterial pressure and cardiac index. In case of massive
bleeding in patients, fluid resuscitation and blood component (packed redThe Journal of Thoracic and Carblood cells, platelets, fresh-frozen plasma) transfusions were continued
until a satisfactory blood volume was reached. Activated recombinant
factor VII was administered in case of refractory hemorrhage to control
bleeding.20 No clotting formation in the circuit was observed after this pro-
cedure. If cardiopulmonary resuscitation was performed before ECLS and
brain injury was suspected, hypothermia was rapidly initiated and main-
tained for 48 hours at a temperature between 32C and 34C.21 Transeso-
phageal ultrasonography was performed every 12 hours (or if clinical
evidence of patient hemodynamic conditions changed) to evaluate cardiac
function and cardiac recovery.
Lung-protective ventilation was adopted, and daily thoracic ultrasonog-
raphy22 was performed to evaluate pulmonary conditions and eventually
pulmonary recovery. A Swan-Ganz catheter (Edwards Lifesciences, Irvine,
Calif) was inserted to evaluate wedge pressure and mixed venous oxygen
saturation. Heparin administration was delayed in case of bleeding, allow-
ing time for surgical hemostasis to be performed; it was started when the
absence of active bleeding was confirmed, at 16.7  19 hours (range,
2.5-72 hours) from ECLS deployment, and titrated by bedside measure-
ment of activated partial thromboplastin time (target value, 40-50 seconds)
and activated clotting time (target value, 160-180 seconds) every 2 hours.
An intra-aortic balloon pump was inserted in 2 patients with CA and pro-
found myocardial dysfunction, thus reducing cardiac afterload and
promoting myocardial recover.
During ECLS treatment, additional specific modules were added to the
ECLS circuit when needed for renal (continuous VV hemofiltration, n¼ 7)
and hepatic (n ¼ 2) function, or in case of sepsis (endotoxin removal car-
tridge, n ¼ 3). Procedures performed during ECLS are summarized in
Table 2. Patients were considered ready for weaning from VV-ECLS
when the pump flow could be reduced to 1.5 to 2 L/min and an arterial
saturated oxygen level of at least 90% was maintained. Weaning from
VA-ECLS was instituted with mild inotropic support, progressivelydiovascular Surgery c Volume 145, Number 6 1619
FIGURE 1. Flow-chart of management of polytraumatized patients (reported as absolute number and %) and hospital sites of ECLS deployment. ED,
Emergency department; ICU, intensive care unit; OR, operating room; ECLS, extracorporeal life support.
TABLE 2. Extracorporeal life support techniques, modalities, and
procedures
Patient characteristics (18 patients) Data (mean ± SD; min-max)
ECLS type
VA 14 (78%)
VV 4 (22%)
Cannula insertion technique:
Surgical 0 (0%)
Percutaneous 18 (100%)
CA before ECLS 11 (61%)
Heparin administration delay from ECLS
start (h)
16.7  19 (2.5-72)
rfVIIa administration 13 (72%)
ECLS apply location
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Sreducing ECLS flow and evaluating cardiac ejection fraction by transeso-
phageal ultrasonography. If a flow of 1 L/min could be reached with
good hemodynamic stability (stable mean arterial pressure, low inotropic
support request, good ejection fraction), the patient was considered ready
for weaning, because cardiac function had recovered. Successful weaning
was considered as weaning from ECLS followed by survival for more than
48 hours. Survival was defined as weaning from ECLS followed by dis-
charge from the hospital.
Statistical Analysis
All statistical analyses were performed with the Statistical Package for
the Social Sciences version 19.0 for Windows (SPSS Inc, Chicago, Ill).
Categoric variables were expressed as percentages and evaluated with
the chi-square or Fisher exact test. Continuous variables were expressed
as mean standard deviation (minimum andmaximum values are reported
in brackets) and evaluated by the Student t test or Wilcoxon rank-sum test.
In addition, receiver operating characteristic (ROC) curves were used to di-
chotomize continuous variables based on a cutoff value. Univariate and
multivariate analyses were used to determine the independent predictors
of unsuitability and unsuccessful ECLS treatment. Univariate analysis
was conducted using the chi-square or Fisher exact test (as appropriate)
for categoric data and the Student t test or the Wilcoxon rank-sum test
(as appropriate) for measurement data. Potential predictors with a P value
less than .05 on univariate analysis were included in multivariate analysis,
performed using stepwise logistic regression, to identify independent pre-
dictors. In the univariate and multivariate analyses, an odds ratio (OR) and
a confidence interval (CI) with a reliability of 95.0% were obtained for all
significant predictors. All P values are 2 tailed.
Emergency department 6 (33%)
Operating room 2 (11%)
ICU 10 (56%)
SD, Standard deviation; ECLS, extracorporeal life support; VA, venoarterial;
VV, venovenous; CA, cardiac arrest; rfVIIa, recombinant factor VII activated; ICU,
intensive care unit.RESULTS
Of 30 ECLS team alerts in 18 patients (60%), ECLS was
deployed according to a refractory but potentially reversible1620 The Journal of Thoracic and Cardiovascular Surclinical setting. The ECLS device was implanted in 6
patients (33%) in the emergency department, in 2 patients
(11%) in the operating room, and in 10 patients (56%) in
the intensive care unit, according to patients’ clinical status,
particularly their hemodynamic and respiratory instability
(Figure 1). Twelve patients (66.7%) underwent previous
computed tomography evaluation; their demographic and
clinical data are summarized in Table 1. ECLS was startedgery c June 2013
TABLE 3. Comparison of pre-extracorporeal life support
demographic, clinical, instrumental, and laboratory characteristics
between success (n ¼ 14) and failure (n ¼ 4) groups with statistical
evaluation results
Patient characteristics
ECLS success
(14 patients, 78%)
ECLS failure
(4 patients, 22%) P
Age (y) 47  17.6 43  19.7 .7085
Gender Male, 71%;
female, 29%
Male, 50%;
female, 50%
.569
ISS 46.5  16.3 65  9.6 .0365
CA 50% 100% .278
CA (min) 56.43  24.27 78.75  8.54 .0006
ECLS insertion location 72% ICU; 14%
OR; 14% ER
100% ER .0058
ECLS type (VA vs VV) 10 (71%) VA;
4 (29%) VV
4 (100%) VA .5959
Heparin-free time
on ECLS (h)
20.71  19.8 2.5  1.3 .0905
IABP 11% 0% .9202
pH 7.18  0.15 6.85  0.11 .0011
PaO2/FIO2 before ECLS 150.4  95.1 177.5  55 .598
PaCO2 before ECLS
(mm Hg)
52.95  8.8 62.5  7 .0666
BL concentration
(mmol/L)
7.11  5.26 18.6  3 .0008
IS (mg/kg/min) 192.1  50.6 307.5  30.9 .0006
Active bleeding 80% 100% .7998
Blood units infused 11.86  5.3 18.75  3.3 .015
Hemoglobin (g/dL) 5.94  0.42 5.35  0.26 .01
Time trauma-ECLS
(min)
351.786  242.12 385  103.44 .695
Time active bleeding
(min)
201.4  90.9 385  103.4 .0032
rfVIIa administration 64% 100% .5465
rfVIIa administration
during ECLS
50% 100% .278
Data are presented as media  standard deviation. The IS is calculated by the
following formula: IS (mg/kg/min): dosages of dopamine þ dobutamine (mg/kg/
min) þ (dosages of epinephrine þ norepinephrine þ isoproterenol [mg/kg/
min])3 100þdosage of milrinone (mg/kg/min)3 15. ECLS, Extracorporeal life sup-
port; ISS, injury severity score; CA, cardiac arrest; VA, venoarterial; VV, venovenous;
IABP, intra-aortic balloon pump; PaO2, arterial oxygen tension; FIO2, inspired oxygen
fraction; PaCO2, arterial carbon dioxide tension; rfVIIa, recombinant factor VII acti-
vated; ICU, intensive care unit; OR, operating room; ER, emergency room.
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Sat 359.176  216.606 (145-950) minutes from trauma. CA
was observed in 11 patients before ECLS, and in 6 of these
patients CA began during advanced cardiac life support ma-
neuvers (Table 2). No complication during the cannulation
procedure was observed.
Extracorporeal Life Support Success Versus Failure
In 4 patients (22.2%) in the ECLS failure group, ECLS
treatment failed because of the inability to maintain ade-
quate ECLS flow and patient perfusion. In this group,
ECLS was stopped after a mean of 3.075  0.65 (2.5-4)
hours.
In 14 patients (77.8%) in the ECLS success group, ECLS
treatment was successful and maintained until the treatment
objectives were obtained or death occurred. The differences
in demographics and clinical, instrumental, and laboratory
characteristics between groups were analyzed (Table 3).
The baseline clinical and demographic characteristics
were similar between the groups; the only differences ob-
served were related to the pre-ECLS ISS, active bleeding
time, CA duration, and inotropic score (IS).23,24 The
patients with ECLS failure demonstrated significantly
greater ISS (65  9.6 vs 46.5  16.3, P ¼ .0365), active
bleeding time (385  103.4 minutes vs 201.4  90.9
minutes, P ¼ .0032), CA duration (78.75  8.54 minutes
vs 56.4  24.27 minutes, P ¼ .0006), and IS
(307.5  30.9 vs 192.1  50.6, P ¼ .0006).
The 2 groups showed no significant difference in bio-
chemical and hematologic profiles. The only differences
observed were related to the pre-ECLS pH, blood lactate
(BL) level, hemoglobin blood concentration, and blood
units infused. Patients with ECLS failure demonstrated sig-
nificantly higher BL level (18.6 3 mmol/L vs 7.11 5.26
mmol/L, P¼ .0008) and blood units infused (18.75 3.3 vs
11.86  5.3, P ¼ .015), and significantly lower pH
(6.85  0.11 vs 7.18  0.15, P ¼ .0011) and hemoglobin
(5.35  0.26 g/dL vs 5.94  0.42 g/dL, P ¼ .01).
In addition, for simplifying preimplantation evaluation of
the patients’ pre-ECLS parameters tested, ROC curves were
used to dichotomize continuous variables based on a cutoff
value, corresponding with the highest Youden index
(Figure 2). These cutoff values were used successively to
identify independent predictors of unsuitability and unsuc-
cessful ECLS treatment with univariate and multivariate
analyses. On the basis of the ROC curves, the cutoff values
were greater than 63 for ISS, greater than 60minutes for CA,
less than 7.01 for pH (mean of last 3 evaluations), greater
than 14.4 mmol/L for BL (mean of last 3 evaluations),
greater than 270 mg/kg/min for IS, greater than 22 for total
blood units, less than 6.7 g/dL for hemoglobin (mean of
last 3 evaluations), and more than 200 minutes for bleeding
time. These dichotomized variables and ‘‘emergency de-
partment ECLS implantation,’’ analyzed with univariate
analysis, are significant predictors associated with ECLSThe Journal of Thoracic and Cartreatment unsuitability and failure (Table 4). From these sig-
nificant predictors, by usingmultivariate regression analysis
(Table 5), only ISS greater than 63 (OR, 4.27; CI, 1.37-
13.31; P ¼ .0407), pH less than 7.01 (OR, 7.17; CI, 2.480-
20.752; P ¼ .0137), and BL greater than 14.4 mmol/L
(OR, 12.51; CI, 4.47-34.97; P ¼ .0251) were significantly
associatedwith ECLS failure and individuated as strong pre-
dictors of ECLS unsuitability and failure.Extracorporeal Life Support Treatment Efficacy
In the ECLS success group, the mean duration of treat-
ment was 128.7  113 hours (range, 24-384 hours), withdiovascular Surgery c Volume 145, Number 6 1621
FIGURE 2. Pre-ECLS parameters tested by ROC curves to recognize a cutoff value (criterion) corresponding to the highest Youden index for all significant
different parameters between the ECLS failure and success groups. The sensitivity, specificity, and criterion are reported in boxes for all parameters tested.
pH pre-ECLS value is the mean of at least 3 evaluations.BL, Blood lactate (the value represents the mean of the last 3 pre-ECLS start evaluations [mmol/L]);
BT, bleeding time (before ECLS start [min]);BU, blood units (infused before ECLS start);CA, cardiac arrest (min);Hb, hemoglobin (the value represents the
mean of the last 3 pre-ECLS start evaluations [g/dL]); IS, inotropic score (mg/kg/min); ISS, injury severity score.
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Ssignificantly longer support time required for VV-ECLS
(204 28 hours), whereas for VA-ECLS, the mean duration
was shorter, 98.8  121.3 hours (P ¼ .018). During ECLS,
damage control surgery was performed in 3 patients, with
no bleeding complications.TABLE 4. Univariate analysis of pre-extracorporeal life support
implantation characteristics associated with extracorporeal life
support failure (predictors of extracorporeal life support unsuitability)
Patient data OR 95% CI Z statistic
P
value
ISS>63 1.8 1.193-2.724 2.088 .037
CA>60 min 2.96 1.258-6.951 2.102 .035
Emergency department
application
4.5 1.258-6.951 2.316 .0206
pH<7.01 (mean of last
3 evaluations)
1.8 1.193-2.715 2.088 .037
Lactate>14.4 mmol/L
(mean of last 3 evaluations)
3.9 1.860-8.177 2.360 .0183
IS>270 mg/kg/min 8.1 2.775-23.643 2.553 .0107
Total blood units>22 7.2 1.09-25.019 2.345 .0221
Hemoglobin<6.7 g/dL
(mean of last 3 evaluations)
7.8 1.04-5.819 2.276 .0168
Bleeding time>200 min 6 0.97-5.365 2.012 .0234
OR, Odds ratio; CI, confidence interval; ISS, injury severity score; CA, cardiac arrest;
IS, inotropic score (mg/kg/min ¼ dopamine þ dobutamine þ 15 3 milrinone þ
100 3 epinephrineþ100 3 norepinephrineþ100 3 isoprotenolol).
1622 The Journal of Thoracic and Cardiovascular SurArterial blood gas analysis, performed before ECLS and
every 2 hours after the deployment, showed significant im-
provement of PaO2/inspired oxygen fraction, arterial carbon
dioxide tension, and pH, with normalization of all arterial
blood gas values at 3.5  1.5 hours (range, 2-4 hours)
(Figure 3). A comparable trend was registered in mean arte-
rial pressure, which was promptly enhanced by ECLS
initiation (55.68  12.45 to 73.45  9.11 after 2  1.2
hours, P < .0005). IS decreased from 192.1  50.6 to
115.68  48.25 (P<.0005). A similar trend was recorded
for BL concentration: Before ECLS, the mean BL concen-
tration was 7.11  5.26 (2.8-18.2) mmol/L, whereas afterTABLE 5. Multivariate analysis (multivariate logistic regression
stepwise model) of significant predictors associated with
extracorporeal life support failure revealed by univariate analysis
Patient data
Regression
coefficient SEM OR 95% CI
P
value
ISS>63 1.45273 0.1754 4.2748 1.373-13.314 .0407
pH<7.01 (mean of
last 3 evaluations)
1.97044 0.1716 7.1738 2.480-20.752 .0137
BL>14.4 mmol/L
(mean of last 3
evaluations)
2.52623 0.69933 12.5063 4.473-34.974 .0251
SEM, Standard error of mean; OR, odds ratio; CI, confidence interval; ISS, injury
severity score; BL, blood lactate.
gery c June 2013
FIGURE 3. ECLS success group. Arterial blood gas analysis parameters are shown from pre-ECLS to 12 hours left. The connection draws (with P value)
were between pre-ECLS and the first significantly different value for any parameter. Values are expressed as mean standard deviation. pH pre-ECLS value
is the mean of at least 3 evaluations. P value refers to the first statistically significant variation of each parameter from ECLS start. ECLS, Extracorporeal life
support; PCO2, carbon dioxide tension (pre-ECLS value is the mean of at least 3 evaluations [mm Hg]); PO2/FIO2, oxygen tension/inspired oxygen fraction
(pre-ECLS value is the mean of at least 3 evaluations).
Bonacchi et al Evolving Technology/Basic Science
E
T
/B
S6 hours from ECLS start, there was a significant improve-
ment in this value to 2.16  1.38 (0.5-3.8) mmol/L
(P ¼ .004) (Figure 4).
An intra-aortic balloon pump (used only in VA-ECLS)
was inserted in 2 patients (14.3% of VA-ECLS). In case
of sepsis or ongoing renal and hepatic failure, additional
support was given to the patient by using the continuous
VV hemofiltration device (n ¼ 7, 50%), plasmapheresis,
the detoxification device (n¼ 2, 14.3%), and endotoxin re-
moval cartridge (n¼ 3, 21.4%). Renal replacement therapy
was successfully performed, allowing the kidneys to re-
cover. Hepatic failure was effectively treated by removing
large lipophilic molecules from plasma. In case of septic
shock, maximal treatment was ensured by integrating an en-
dotoxin removal cartridge in the circuit. In 7 patients (50%)
in the ECLS success group with extensive craniocerebral
trauma, ECLSwas used to allow time for brain death assess-
ment and was continued to support organ donation, which
was possible in all cases (100% effectiveness). One patient
did not complete the organ donation procedure because
of the relatives’ opposition. The liver from all other patients
(n ¼ 6) and 3 kidneys were donated.
Among the 7 remaining patients (50% of ECLS success
group), 2 (28.6%) died of septic multiple organ failure (at
days 7 and 16 of treatment) during ECLS, and 5 (71.4%)
survived to discharge. All survivors were discharged from
the intensive care unit to hospital wards and followedThe Journal of Thoracic and Carthe necessary rehabilitative programs available. After reha-
bilitation, all the survivors returned home; only 1 patient
(20%) was in cerebral performance category 2, and the re-
maining patients (n ¼ 4, 80%) were in category 1 and able
to manage their own affairs before the index event.
ECLS-related complications were observed in 2 patients:
1 leg ischemia due to femoral artery cannulation and 1 ox-
ygenator failure due to clot formation (after 13 days of use).
The first complication was promptly solved by moving vas-
cular access to the axillary artery, and the second complica-
tion was detected early enough because of continuous
monitoring and was corrected with the substitution of the
membrane lung. The results and complications in the
ECLS success group are shown in Table 6.
DISCUSSION
Since the first pioneering experience of ECLS used in
a patient with trauma in 1971,12 many advances in technol-
ogy, materials, and intensive care have occurred.10,11 The
use of ECLS in cardiogenic shock and pulmonary failure
of different causes has been accepted, and a new group of
indications is being considered.
Severe trauma is a serious matter not only because it
causes disablement and numerous deaths but also because
the social cost is even more dramatic, with regard to the
large number of young people involved.1 Moreover,
mortality rates due to major trauma are still high, despitediovascular Surgery c Volume 145, Number 6 1623
FIGURE 4. ECLS success group. Hemodynamic parameters are shown from pre-ECLS to 12 hours left. The connection draws (with P value) were between
pre-ECLS and the first significant different value for any parameter. Values are expressed as mean standard deviation.P value refers to the first statistically
significant variation of each parameter from ECLS start. BL, Blood lactate (pre-ECLS value is the mean of at least 3 evaluations [mmol/L]); ECLS, extra-
corporeal life support (pre-ECLS value is the mean of at least 3 evaluations); IS, inotropic score (pre-ECLS value is the mean of at least 3 evaluations
[mg/kg/min]); MAP, mean arterial pressure (pre-ECLS value is the mean of at least 3 evaluations [mm Hg]).
Evolving Technology/Basic Science Bonacchi et al
E
T
/B
Sadvanced treatments. The first experiences of ECLS in
trauma care have been reported,5,14 with encouraging
outcomes, suggesting that ECLS seems to be a valid
option in patients with severe trauma and refractory
cardiopulmonary failure, preventing potentially evolving
shock and maintaining tissue perfusion, oxygenation, and
organ function.
Actual ECLS devices are small and portable; suitable for
both intra- and inter-hospital transport; and easy, fast, and
safe to implant, even in an out-of-hospital scenario.25 In
the current study and the study by Arlt and colleagues,5
anticoagulation can be safely delayed for 48 or 72
hours because of improved biocompatibility. Anticoagula-
tion can be maintained on mild levels, reducing bleeding
complications during ECLS, which is the first problem in
this setting and mainly accepted as a major contraindica-
tion to the treatment. In adjunct, the current study and
the study by Steinbrueckner and colleagues26 found that
blood cell consumption is decreased by actual centrifugal
pumps, significantly reducing the need for blood transfu-
sions and their related complications. All of these impor-
tant advantages have made ECLS a safe and feasible
technique, which has been demonstrated in many
conditions.9-11 In patients with polytrauma, severe
coagulopathies and preexisting bleeding remain mostly
accepted as contraindications to ECLS, and no definitive1624 The Journal of Thoracic and Cardiovascular Surproof of its safety, feasibility, and effectiveness in
polytrauma cases has been reported.
Our study presents a specific category of patients with
polytrauma with extremely severe clinical conditions and
refractory cardiopulmonary failure. The study patients
were supported by a high level of inotropes or intra-aortic
balloon pump and ventilator maximal support, and the
majority of these patients (61.1%) received ECLS with pro-
longed continuous cardiac massage. In all patients, the pre-
ECLS blood gas analysis data were poor (pH, PaO2, arterial
carbon dioxide tension, BL). The mortality predicted from
the ISS score (mean, 53  17) and prolonged cardiopulmo-
nary resuscitation was greater than 90%. Thus, it is clear
that the application of ECLS in these patients in critical
condition, as evidenced by the results of our study, can
reduce mortality to a more acceptable 64.3% (9 deaths in
14 patients, considering the ECLS success group), with
an important possibility of organ recovery for donation.
After supporting vital function by ECLS, the first goal in
the treatment of these patients remains the restoration of
blood coagulation. As did Arlt and colleagues,5 we initially
started heparin-free ECLS support (16.7  19 hours after
initiation). The treatment of hemorrhagic status and coagu-
lation disorders was carried out according to the recommen-
dations for blood component transfusion in patients with
trauma.3 When clinical and hemocoagulation laboratorygery c June 2013
TABLE 6. Extracorporeal life support success group: Modalities,
results, complications, and outcome
Patient characteristics
Value (mean ± SD;
max-min)
ECLS modality
VV-ECLS 2 (14.3%)
VA-ECLS 12 (85.7%)
On ECLS time (h) 128.7  113 (24-384)
VV-ECLS time (h) 204  28 (165-231)
VA-ECLS time (h) 98.8  121.3 (24-384)
Damage-control surgery 3 (21.4%)
IABP 2 (14.3%)
Adjunctive treatment modules
CVVH 7 (50%)
Endotoxin removal cartridge 3 (21.4%)
Hepatic 2 (14.3%)
Complications
Leg ischemia 1 (7.1%)
Oxygenator failure 1 (7.1%)
Outcome
Cerebral death and organ donation 7 (50%)
Death due to septic multiple organ failure 2 (28.6%)
Survival 5 (71.4%)
Survivors’ (n ¼ 5) cerebral performance
category (after rehabilitation)
Category 4 0 (0%)
Category 3 0 (0%)
Category 2 1 (20%)
Category 1 4 (80%)
SD, Standard deviation; ECLS, extracorporeal life support; VV, venovenous; VA,
venoarterial; IABP, intra-aortic balloon pump; CVVH, continuous venovenous hemo-
filtration.
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maintain an activated partial thromboplastin time range
equal to 50 to 60 seconds. During the phase of hemostatic
function treatment, patients were maintained in a normo-
thermic state by the ECLS system to avoid the negative he-
mocoagulative effects of hypothermia.3,4 Moreover, blood
acidosis (and its negative effects on coagulation system)
could be corrected by ECLS.
In VV configuration as respiratory support, ECLS allows
a more protective ventilation strategy, reducing ventilator-
induced lung injury and allowing time for lung rest and
recovery. Patients with thoracic trauma and pulmonary con-
tusions resulting in post-traumatic acute respiratory distress
syndrome, in which ventilation management is challenging,
can be safely sustained by ECLS for days, until pulmonary
function is restored and weaning is possible.
As cardiopulmonary support in the VA setting, ECLS is
effective in maintaining hemodynamic stability and sys-
temic perfusion when fluid resuscitation and inotropic
infusion are insufficient. Management of bleeding sites is
necessary to reach stable hemostasis; thus, adequate blood
flow in the circuit is provided and ECLS procedure is effec-
tive. Institution of ECLS in emergency situations (eg,The Journal of Thoracic and Carduring CA) is possible and produces good outcomes. In
the current study, ECLS was started during resuscitation
maneuvers in 6 patients, 2 of whom were successfully sup-
ported allowing the goal to be achieved (1 survival and 1
organ donation). The reported parameters and statistical
analysis strengthen these results, confirming that ECLS is
effective in rapidly improving respiratory and hemody-
namic function, as reported by Arlt and colleagues5 and
Huang and colleagues.14
ECLS proved to be effective in expanding the donor pool
and allowing time for brain death assessment, when
hemodynamic instability threatens to interrupt it. However,
the clinical limitations and suitability of ECLS treatment
are yet to be observed in this category of patients.5,14
Currently, there is no identified, reported predictor of
ECLS success based on the patient’s clinical status before
implantation. The identification of predictors for ECLS
unsuitability and failure could result in better
identification of patients with a greater efficacy and better
allocation of resources and cost-effectiveness.
By focusing on an analysis of ECLS success, we tried to
evaluate the preimplant parameters in those patients in
whom injuries were too severe for ECLS and ECLS was
not appropriate. We considered all of the accessible clinical,
instrumental, and laboratory parameters in an emergency
setting that did not require an invasive procedure or time-
consuming measurements. The data can be evaluated within
minutes after a patient’s admittance to the emergency de-
partment. To make the evaluation as simple and fast as pos-
sible, all continuous variables were dichotomized by ROC
curves for estimation of cutoff values with the best sensibil-
ity and specificity. From our data, the univariate and multi-
variate statistical analyses showed that the following
parameters had the highest negative impact: BL greater
than 14.4 mmol/L, pH less than 7.01 among laboratory
values, and ISS greater than 63 among clinical data. No ul-
trasonography or hemodynamic parameter contributed sig-
nificantly to the prediction of ECLS success or failure. CA
was relatively significant as a predictor (on univariate anal-
ysis but not on multivariate analysis) only if it lasted more
than 60 minutes.
These results seem to suggest that ECLS should be
avoided when tissue perfusion is strongly impaired for an
extended time; when the patient is in severe shock status
for a long time, ECLS treatment is probably not indicated.
The patient most likely has entered the irreversible stage
of shock, dominated by disseminated intravascular coagula-
tion and severely altered permeability of the microcircula-
tion.27 This irreversible stage of shock is clinically
characterized by a severe and irreversible hemorrhagic
status, and is therefore uncontrollable and uncontainable
(even with advanced therapeutic solutions, eg, coagulation
factors and activated factor VII). In our experience, it is im-
possible in this advanced stage of shock, even with ECLS,diovascular Surgery c Volume 145, Number 6 1625
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acidosis, coagulopathy, and inadequate tissue perfusion
and oxygen supply. ECLS always was considered as the
last option and was deployed in those patients in whom
maximal advanced therapies had been exhausted with no
improvement. When the ECLS team decided to begin
ECLS, there was collegial conviction that no other treat-
ment option was available and that awaited mortality was
100%. Even in this clinical setting, observed mortality
was 64.3% (9 deaths in 14 patients), which was lower
than we expected.
Study Limitations
Several limitations are important to note in the current
study. First, the number of enrolled patients was not large
enough to yield completely persuasive and conclusive
results. Second, different clinical scenarios were present
in the polytraumatized patients, and the evaluation may be
nonhomogeneous. Third, some selection bias for the treat-
ment may exist. The emergency department doctor was
the first decision-maker for ECLS team activation; there-
fore, it may be assumed that the patients’ conditions were
difficult to manage.
CONCLUSIONS
ECLS is a safe and feasible technique. ECLShas proved to
be lifesaving inmultiply injured patients with refractory car-
diopulmonary failure when it is promptly initiated in a spe-
cialized center. Advanced management of patients with
polytrauma should include ECLS in case of refractoriness
of the clinical conditions to conventional treatments and if
no predictor of ECLS failure is present. Our data allowed
the identification of strong predictors of ECLSnonsuitability
and success in polytraumatized patients, whichmay be help-
ful in decidingwhether an ECLS device should be implanted
in severely complex and compromised cases. Because ECLS
does not impede conventional therapies, it should be insti-
tuted early alongside them, not only to give the patient the
maximal chance of survival but also as a newway of expand-
ing the donor pool for organ transplantation. Future improve-
ments in materials and techniques are expected to make
ECLS even easier and safer to manage, leading to a further
extension of its use in severely injured patients.
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